<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806065</url>
  </required_header>
  <id_info>
    <org_study_id>2076-CL-002</org_study_id>
    <nct_id>NCT00806065</nct_id>
  </id_info>
  <brief_title>Study of ENMD-2076 in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the safety, tolerability, maximum tolerated dose, and
      clinical benefit of treatment with ENMD-2076 administered orally once daily over a range of
      doses in patients with relapsed or refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of ENMD-2076</measure>
    <time_frame>Within first 35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlative studies of activity</measure>
    <time_frame>throughout the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>Each cycle of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENMD-2076</intervention_name>
    <description>Oral capsules, once daily in 28-day cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          1. Histological evidence of MM and evidence of relapse or refractory disease. Patients
             with non secretory myeloma or plasmacytoma only will be excluded.

          2. Patients must have failed thalidomide, lenalidomide, or velcade or be intolerant or
             ineligible to receive these agents.

          3. Age â‰¥18 years.

          4. ECOG performance status 0-2.

          5. Patients must have adequate organ and marrow function

        Major Exclusion Criteria:

          1. Prior cytotoxic chemotherapy or investigational agent within 28 days or autologous
             stem cell transplant within 6 months of receiving study drug ENMD-2076.

          2. Prior radiation therapy to &gt; 25% of bone marrow forming bones (i.e., pelvis).

          3. Concomitant corticosteroid therapy in doses greater than 10 mg daily of prednisone (or
             equivalent) if given for management of co-morbid conditions.

          4. Have unstable angina pectoris or recent myocardial infarction (within 6 months.

          5. Have uncontrolled hypertension or congestive heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>EntreMed, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

